Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) announced today that additional data supporting the Company’s novel, investigational anti-cancer therapeutic, Supinoxin™ (RX-5902), for the treatment of triple negative breast cancer, were presented at the 14th Annual Targeted Anticancer Therapeutics Congress (TAT 2016), held in Washington, DC March 21- 23, 2016.